FRINK Linked Data Fragments server

Matches in Wikidata for { <http://www.wikidata.org/entity/Q39152521> ?p ?o ?g. }

• Q39152521 description "2017 nî lūn-bûn" @default.
• Q39152521 description "2017年の論文" @default.
• Q39152521 description "2017年論文" @default.
• Q39152521 description "2017年論文" @default.
• Q39152521 description "2017年論文" @default.
• Q39152521 description "2017年論文" @default.
• Q39152521 description "2017年論文" @default.
• Q39152521 description "2017年论文" @default.
• Q39152521 description "2017年论文" @default.
• Q39152521 description "2017年论文" @default.
• Q39152521 description "2017年论文" @default.
• Q39152521 description "2017年论文" @default.
• Q39152521 description "2017年论文" @default.
• Q39152521 description "2017년 논문" @default.
• Q39152521 description "article científic" @default.
• Q39152521 description "article scientific" @default.
• Q39152521 description "article scientifique" @default.
• Q39152521 description "articol științific" @default.
• Q39152521 description "articolo scientifico" @default.
• Q39152521 description "artigo científico" @default.
• Q39152521 description "artigo científico" @default.
• Q39152521 description "artigo científico" @default.
• Q39152521 description "artikel ilmiah" @default.
• Q39152521 description "artikull shkencor" @default.
• Q39152521 description "artikulong pang-agham" @default.
• Q39152521 description "artykuł naukowy" @default.
• Q39152521 description "artículo científico publicado en 2017" @default.
• Q39152521 description "artículu científicu espublizáu en 2017" @default.
• Q39152521 description "bilimsel makale" @default.
• Q39152521 description "bài báo khoa học" @default.
• Q39152521 description "naučni članak" @default.
• Q39152521 description "scienca artikolo" @default.
• Q39152521 description "scientific article published on 17 July 2017" @default.
• Q39152521 description "scientific article published on 17 July 2017" @default.
• Q39152521 description "scientific article published on 17 July 2017" @default.
• Q39152521 description "teaduslik artikkel" @default.
• Q39152521 description "tieteellinen artikkeli" @default.
• Q39152521 description "tudományos cikk" @default.
• Q39152521 description "vedecký článok" @default.
• Q39152521 description "vetenskaplig artikel" @default.
• Q39152521 description "videnskabelig artikel" @default.
• Q39152521 description "vitenskapelig artikkel" @default.
• Q39152521 description "vitskapeleg artikkel" @default.
• Q39152521 description "vědecký článek" @default.
• Q39152521 description "wetenschappelijk artikel" @default.
• Q39152521 description "wissenschaftlicher Artikel" @default.
• Q39152521 description "επιστημονικό άρθρο" @default.
• Q39152521 description "мақолаи илмӣ" @default.
• Q39152521 description "наукова стаття, опублікована в липні 2017" @default.
• Q39152521 description "научна статия" @default.
• Q39152521 description "научная статья" @default.
• Q39152521 description "научни чланак" @default.
• Q39152521 description "научни чланак" @default.
• Q39152521 description "מאמר מדעי" @default.
• Q39152521 description "مقالة علمية نشرت في 17 يوليو 2017" @default.
• Q39152521 description "১৭ জুলাই ২০১৭-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ" @default.
• Q39152521 description "บทความทางวิทยาศาสตร์" @default.
• Q39152521 description "სამეცნიერო სტატია" @default.
• Q39152521 name "ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC)." @default.
• Q39152521 name "ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC)." @default.
• Q39152521 name "ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC)." @default.
• Q39152521 type Item @default.
• Q39152521 label "ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC)." @default.
• Q39152521 label "ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC)." @default.
• Q39152521 label "ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC)." @default.
• Q39152521 prefLabel "ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC)." @default.
• Q39152521 prefLabel "ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC)." @default.
• Q39152521 prefLabel "ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC)." @default.
• Q39152521 P1433 Q39152521-5720D234-AC26-4CB4-B1FE-87929760A976 @default.
• Q39152521 P1476 Q39152521-AD7BCDAA-7698-4544-BD9B-633D782F1DE2 @default.
• Q39152521 P2093 Q39152521-0AA2309C-982E-4A13-B82A-C8641943E1AB @default.
• Q39152521 P2093 Q39152521-1733F37A-B9BD-4236-B603-603C939269AE @default.
• Q39152521 P2093 Q39152521-302D1B71-B1AF-44E1-907F-C8DA3BCB4BF6 @default.
• Q39152521 P2093 Q39152521-42395D17-F312-46DB-8DD3-FB3504DDD51D @default.
• Q39152521 P2093 Q39152521-42BB31D0-3299-43D9-B764-37B65CCC6EFC @default.
• Q39152521 P2093 Q39152521-68375639-747B-4849-AB95-E04E4D4A1E41 @default.
• Q39152521 P2093 Q39152521-85015894-95B4-494E-B8F5-F6C0F503D2DB @default.
• Q39152521 P2093 Q39152521-9F53D695-8B56-4AF2-AD70-C6BBD5C481C9 @default.
• Q39152521 P2093 Q39152521-B10AB5A2-F5FA-4906-8DFF-EBE189083D25 @default.
• Q39152521 P2093 Q39152521-C364888F-AAF7-4790-B800-677895F6294E @default.
• Q39152521 P2093 Q39152521-D0D0D241-3B1E-4A5B-A2CC-DFADFBFE5F63 @default.
• Q39152521 P2093 Q39152521-DE9CCF6C-A895-4161-950A-CBE8CA82981B @default.
• Q39152521 P2093 Q39152521-DFCB8FFD-B4A0-4CE2-986A-EF882E6BD06F @default.
• Q39152521 P2093 Q39152521-FB009909-53BE-4623-91DB-72A58093EE83 @default.
• Q39152521 P304 Q39152521-8E57319F-D175-40D9-9294-E54B265CAC08 @default.
• Q39152521 P31 Q39152521-D4556E04-B2D3-4EB1-8FB2-2E0F7A747A45 @default.
• Q39152521 P356 Q39152521-64CD34FB-B6D3-4CC2-B07F-16D55CCBF5F6 @default.
• Q39152521 P433 Q39152521-C27D4454-0C9C-451E-BAF2-3FEE9774A697 @default.
• Q39152521 P478 Q39152521-98FA3C1D-9EED-4A8D-B3B0-9750AB19D656 @default.
• Q39152521 P50 Q39152521-48ACDD43-D66C-4761-910F-7A4E4D476DC9 @default.
• Q39152521 P50 Q39152521-53466141-5EBD-4012-A423-4FF2350FC6EC @default.
• Q39152521 P50 Q39152521-6BE7FFF1-7BEF-4DA5-B63A-62091B41C51F @default.
• Q39152521 P50 Q39152521-969B9E3A-DE20-4030-98B4-49789D4F3C54 @default.
• Q39152521 P50 Q39152521-AE5526EB-4ACD-442F-BA83-71E40305175C @default.
• Q39152521 P577 Q39152521-2963A562-1290-4F6B-B90F-0F17AF6F9232 @default.
• Q39152521 P698 Q39152521-8A665FB5-C748-44E5-8EC8-BCF7ABA4F323 @default.
• Q39152521 P921 Q39152521-D9382724-2F9F-429D-BF8A-1E740560A7E4 @default.
• Q39152521 P921 Q39152521-F6D8DC80-F3CA-4F55-8CF6-F038B7A96F5F @default.
• Q39152521 P356 J.JTHO.2017.07.005 @default.
• Q39152521 P698 28729021 @default.

• next